Hypofractionated radiation therapy (HFRT)

RADIATION2 trials

Sponsors

NYU Langone Health, Abramson Cancer Center at Penn Medicine

Conditions

GlioblastomaMetastatic Melanoma

Phase 2

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

CompletedNCT02968940

NYU Langone HealthGlioblastoma

Start: 2017-03-17End: 2019-08-29Updated: 2022-06-29

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Active, not recruitingNCT03646617

Abramson Cancer Center at Penn MedicineMetastatic Melanoma

Start: 2018-11-27End: 2027-12-31Updated: 2026-08-17

Related Papers

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Neurological Research and Practice2022-05-2337 citations

A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes

OncoImmunology2021-01-0128 citations

Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma

Neuro-Oncology Advances2021-01-0125 citations